Yale Cancer Center NCTN LAPS

耶鲁大学癌症中心 NCTN LAPS

• 批准号: 10359158
• 负责人: Roy S Herbst
• 金额: $ 48.49万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-08 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10359158
• 关键词: Advanced Malignant Neoplasm; Advocate; American College of Radiology Imaging Network; Award; Biology; Cancer Hospital; Cancer Patient; Caring; Chemicals; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Comprehensive Cancer Center; Connecticut; Cooperative Group Program; Detection; Diagnosis; Disease; Eastern Cooperative Oncology Group; Ensure; Epidermal Growth Factor Receptor; Faculty; Funding; Grant; Gynecologic Oncology; Hospitals; Infrastructure; International; Laboratories; Lead; Leadership; Malignant Neoplasms; Medical Oncology; Mentors; Mentorship; National Cancer Institute; Operations Research; Personnel Staffing; Phase; Physicians; Prevention approach; Program Development; Radiation Oncology; Randomized; Recording of previous events; Research; Research Personnel; Resistance; Resources; Rewards; Role; Science; Scientist; Signal Transduction; Solid; Southwest Oncology Group; Supervision; Support Groups; System; Time; Training; Translational Research; Translations; Universities; Vision; War; Work; Yale Cancer Center; base; cancer therapy; clinical center; drug development; medical schools; member; next generation; patient population; performance site; pilot trial; programmed cell death protein 1; programs; santin; standard of care; success

Project Summary Yale Cancer Center's continuing participation in the NCTN under the leadership of Dr. Charles Fuchs includes not only a solid history of strong and committed accrual to NCTN trials, but strong leadership in the trials efforts at SWOG and other groups. YCC remains committed to prioritizing NCTN trials at all the YCC clinical centers and demonstrates annual accrual beyond estimates developed in our current U10 award. For this current submission, the vision of the YCC leadership is to: 1) continue to prioritize NCTN trials for accrual and develop YCC as a major contributor to group trials with additional contribution of our Care Centers; 2) facilitate and encourage YCC faculty to assume leadership roles in SWOG and other NCTN groups by supporting their time and effort and rewarding these activities; and 3) leverage our NCTN Coordinating Committee (NCC) as a bridge to bring Yale translational science to group activities as the results of our investigator initiated pilot trials become promising for multi-center and randomized questions. In addition to the leadership efforts of Dr. Fuchs, other key SWOG leaders include Drs. Roy Herbst, Daniel Petrylak and Lajos Pusztai. Drs. Peter Glazer, Roy Decker and Alessandro Santin will lead our efforts in the NRG group in addition to Dr. Barbara Burtness who will continue to lead our efforts in the ECOG-ACRIN group. We believe that the science and translational work at YCC has strong potential for incorporation into NCTN programs. Continued work on early phase drug development, EGFR resistance, PD-1 signaling, chemical biology, and new targets in signal transduction through the scientific programs of YCC have strong potential for translation into group trials. Furthermore, with expansion of the Smilow Cancer Hospital Care Centers, we demonstrated a greater opportunity to bring NCTN trials to the greater patient population across the state of Connecticut. This UG1 grant will assist us in developing the appropriate leadership and infrastructure for support of key NCTN group efforts in both accrual and program development.

项目概要 耶鲁大学癌症中心在 Charles 博士的领导下继续参与 NCTN Fuchs 不仅拥有 NCTN 试验的强大和承诺应计的悠久历史，而且 在 SWOG 和其他团体的试验工作中发挥强有力的领导作用。 YCC 仍然致力于 优先考虑所有 YCC 临床中心的 NCTN 试验，并证明年度应计额超出 我们当前的 U10 奖项中制定了估算。对于当前提交的内容， YCC 的领导层是：1) 继续优先考虑 NCTN 试验的权责发生制，并将 YCC 发展为 团体试验的主要贡献者以及我们的护理中心的额外贡献； 2) 促进和 鼓励 YCC 教师在 SWOG 和其他 NCTN 团体中担任领导角色 支持他们的时间和精力并奖励这些活动； 3) 利用我们的 NCTN 协调委员会（NCC）作为将耶鲁大学转化科学引入团体的桥梁 随着我们的研究者发起的试点试验的结果变得有希望在多中心开展活动 和随机问题。除了 Fuchs 博士的领导努力外，SWOG 的其他重要成员 领导者包括博士。罗伊·赫布斯特、丹尼尔·彼得拉克和拉约斯·普兹泰。博士。彼得·格雷泽、罗伊 除 Barbara 博士外，Decker 和 Alessandro Santin 将领导 NRG 小组的工作 Burtness 将继续领导我们在 ECOG-ACRIN 小组的工作。我们相信 YCC 的科学和转化工作具有纳入 NCTN 的巨大潜力 程序。继续致力于早期药物开发、EGFR 耐药、PD-1 信号传导、 化学生物学，以及通过 YCC 科学项目进行信号转导的新目标 具有转化为团体试验的强大潜力。此外，随着 Smilow 的扩展 癌症医院护理中心，我们展示了将 NCTN 试验引入到癌症医院护理中心的更大机会 康涅狄格州的患者人数更多。这笔 UG1 赠款将帮助我们 培养适当的领导力和基础设施以支持 NCTN 集团的主要工作 在权责发生制和计划制定方面。